Investing in the "Delta-9" Revolution

Written By Outsider Club

Posted December 10, 2014

Pain affects more people than cancer, heart disease, and diabetes combined.

Every year, one-third of the country — or 116 million Americans — suffers from chronic pain. More than 15,000 die from dangerous painkillers.

And ineffective pain care costs as much as $635 billion.

But that’s about to change.

A new drug has emerged that has the leading voices of the medical community rallying behind it.

Like Dr. Oz, who, during his interview with Larry King, called this “Delta-9” drug’s pain treatment “hugely beneficial.”

Dr. Richard Besser, ABC News’ chief health and medical editor, has made similar statements about “Delta-9’s” power to treat pain.

And then there’s Dr. Sanjay Gupta, CNN’s chief medical correspondent, who has personally witnessed its impact and reports, “I have seen [‘Delta-9’] quell epilepsy in a child and pain in a grown adult. I’ve seen it help a woman at the peak of her life to overcome the ravages of multiple sclerosis.”

Imagine living in a world where you never suffer from pain.

Where you can enjoy your daily life without being held back by pain…

And without taking lethal or addictive painkillers.

This new “Delta-9” drug could make all of that a reality.

20,000 independent studies have confirmed its efficacy.

105 of these were peer-reviewed clinical studies.

And they found…

  • It is more effective than any single painkiller or narcotic out there.
  • It relieves pain for longer periods of time — without dangerous side effects.
  • It significantly reduces the need for ANY painkillers — to the point of zero.

That’s all very interesting, but as an investor, why should you care?

Well, the market for this new drug is already at $3 billion…

And Forbes expects the U.S. market for “Delta-9” to grow 350% by 2016.

Just take a look at this chart:


But these numbers are just the tip of the iceberg when it comes to “Delta-9’s” growth potential.

CNBC estimates the “Delta-9” market could reach as high as $120 billion globally.

Steve Berg, a former managing director of Wells Fargo Bank, said, “Domestically, we weren’t able to find any market that is growing as quickly.”

And according to the Huffington Post, the market for “Delta-9” “is poised to grow faster than smartphones.”

In fact, this opportunity is so big that a presidential candidate — who has recently accepted a job as the CEO of a “Delta-9” company — made this prediction: “In 20 years, [‘Delta-9’] will amount to 20% of the pharmaceutical market.”

There are three companies we’ve identified that stand to gain the most from this trend. For all the details about how to get into this massive market, simply watch the following presentation.